New paradigms in oncological therapeutics: redefining combination chemotherapy

被引：4

作者：

Brenner, DE ^{[1
]}

机构：

[1] Univ Michigan, Med Ctr, Canc Ctr 2150, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Med Ctr, Geriatr Ctr, Ann Arbor, MI USA

[3] VA Med Ctr, Ann Arbor, MI USA

来源：

ANNALS OF ONCOLOGY | 2002年 / 13卷 / 11期

关键词：

D O I：

10.1093/annonc/mdf349

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1697 / 1698

页数：2

共 13 条

[1]

Belotti D, 1996, CLIN CANCER RES, V2, P1843

[2] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[3] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors [J].

Demetri, GD ;

von Mehren, M ;

Blanke, CD ;

Van den Abbeele, AD ;

Eisenberg, B ;

Roberts, PJ ;

Heinrich, MC ;

Tuveson, DA ;

Singer, S ;

Janicek, M ;

Fletcher, JA ;

Silverman, SG ;

Silberman, SL ;

Capdeville, R ;

Kiese, B ;

Peng, B ;

Dimitrijevic, S ;

Druker, BJ ;

Corless, C ;

Fletcher, CDM ;

Joensuu, H .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) :472-480

[4] Perspectives on the development of a molecularly targeted agent [J].

Druker, BJ .

CANCER CELL, 2002, 1 (01) :31-36

[5] ST1571 (Gleevec™) as a paradigm for cancer therapy [J].

Druker, BJ .

TRENDS IN MOLECULAR MEDICINE, 2002, 8 (04) :S14-S18

[6] Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification [J].

Gorre, ME ;

Mohammed, M ;

Ellwood, K ;

Hsu, N ;

Paquette, R ;

Rao, PN ;

Sawyers, CL .

SCIENCE, 2001, 293 (5531) :876-880

[7]

Hochhaus A, 2001, SCIENCE, V293, P2163

[8] APOPTOSIS AND THE PROGNOSTIC-SIGNIFICANCE OF P53 MUTATION [J].

LOWE, SW ;

BODIS, S ;

BARDEESY, N ;

MCCLATCHEY, A ;

REMINGTON, L ;

RULEY, HE ;

FISHER, DE ;

JACKS, T ;

PELLETIER, J ;

HOUSMAN, DE .

COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, 1994, 59 :419-426

[9] P53-DEPENDENT APOPTOSIS MODULATES THE CYTOTOXICITY OF ANTICANCER AGENTS [J].

LOWE, SW ;

RULEY, HE ;

JACKS, T ;

HOUSMAN, DE .

CELL, 1993, 74 (06) :957-967

[10] TYROSINE KINASE-ACTIVITY AND TRANSFORMATION POTENCY OF BCR-ABL ONCOGENE PRODUCTS [J].

LUGO, TG ;

PENDERGAST, AM ;

MULLER, AJ ;

WITTE, ON .

SCIENCE, 1990, 247 (4946) :1079-1082

← 1 2 →